Moderna, Inc. (NASDAQ:MRNA) Shares Sold by Letko Brosseau & Associates Inc.

Letko Brosseau & Associates Inc. lowered its holdings in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) by 2.9% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 896,425 shares of the company's stock after selling 26,920 shares during the quarter. Letko Brosseau & Associates Inc. owned approximately 0.23% of Moderna worth $25,414,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in MRNA. Deutsche Bank AG lifted its stake in shares of Moderna by 54.7% in the 4th quarter. Deutsche Bank AG now owns 1,894,075 shares of the company's stock valued at $78,756,000 after purchasing an additional 669,614 shares during the last quarter. Tang Capital Management LLC bought a new stake in shares of Moderna in the 4th quarter valued at approximately $12,474,000. Bank of New York Mellon Corp lifted its stake in shares of Moderna by 1.8% in the 1st quarter. Bank of New York Mellon Corp now owns 1,918,248 shares of the company's stock valued at $54,382,000 after purchasing an additional 34,034 shares during the last quarter. Wealthfront Advisers LLC lifted its stake in shares of Moderna by 143.3% in the 1st quarter. Wealthfront Advisers LLC now owns 31,018 shares of the company's stock valued at $879,000 after purchasing an additional 18,268 shares during the last quarter. Finally, OVERSEA CHINESE BANKING Corp Ltd lifted its stake in shares of Moderna by 73.5% during the 1st quarter. OVERSEA CHINESE BANKING Corp Ltd now owns 40,772 shares of the company's stock worth $1,156,000 after acquiring an additional 17,268 shares during the last quarter. Hedge funds and other institutional investors own 75.33% of the company's stock.

Moderna Stock Performance

Shares of Moderna stock traded down $1.96 on Friday, hitting $27.60. The company's stock had a trading volume of 16,270,216 shares, compared to its average volume of 10,964,893. The firm has a fifty day moving average price of $29.20 and a 200-day moving average price of $30.34. The company has a market capitalization of $10.67 billion, a price-to-earnings ratio of -3.16 and a beta of 1.84. Moderna, Inc. has a 1 year low of $23.15 and a 1 year high of $91.99.

Moderna (NASDAQ:MRNA - Get Free Report) last released its quarterly earnings data on Friday, August 1st. The company reported ($2.13) EPS for the quarter, beating analysts' consensus estimates of ($2.99) by $0.86. Moderna had a negative return on equity of 28.69% and a negative net margin of 105.67%. The firm had revenue of $142.00 million for the quarter, compared to analysts' expectations of $116.26 million. During the same period in the prior year, the firm posted ($3.33) earnings per share. The firm's quarterly revenue was down 41.1% on a year-over-year basis. As a group, analysts forecast that Moderna, Inc. will post -9.61 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages recently issued reports on MRNA. William Blair reissued a "market perform" rating on shares of Moderna in a research note on Monday, June 2nd. Barclays reissued an "equal weight" rating on shares of Moderna in a research note on Sunday, July 13th. Evercore ISI set a $32.00 price target on Moderna in a research note on Friday. JPMorgan Chase & Co. set a $26.00 price target on Moderna in a research note on Friday. Finally, UBS Group cut their price target on Moderna from $78.00 to $70.00 and set a "buy" rating on the stock in a report on Friday, May 2nd. Four equities research analysts have rated the stock with a sell rating, seventeen have assigned a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Moderna currently has a consensus rating of "Hold" and a consensus price target of $46.11.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.